| Blinatumomab, a Bispecific T-cell Engager (BiTE®) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications M Zhu, B Wu, C Brandl, J Johnson, A Wolf, A Chow, S Doshi Clinical pharmacokinetics 55, 1271-1288, 2016 | 173 | 2016 |
| Population pharmacokinetic meta-analysis of denosumab in healthy subjects and postmenopausal women with osteopenia or osteoporosis L Sutjandra, RD Rodriguez, S Doshi, M Ma, MC Peterson, GR Jang, ... Clinical pharmacokinetics 50, 793-807, 2011 | 103 | 2011 |
| Population pharmacokinetic analysis of denosumab in patients with bone metastases from solid tumours L Gibiansky, L Sutjandra, S Doshi, J Zheng, W Sohn, MC Peterson, ... Clinical pharmacokinetics 51, 247-260, 2012 | 81 | 2012 |
| Pharmacodynamics-mediated drug disposition (PDMDD) and precursor pool lifespan model for single dose of romiplostim in healthy subjects YMC Wang, W Krzyzanski, S Doshi, JJ Xiao, JJ Pérez-Ruixo, AT Chow The AAPS journal 12, 729-740, 2010 | 76 | 2010 |
| Population pharmacokinetics of rilotumumab, a fully human monoclonal antibody against hepatocyte growth factor, in cancer patients M Zhu, S Doshi, PO Gisleskog, KS Oliner, JJP Ruixo, E Loh, Y Zhang Journal of Pharmaceutical Sciences 103 (1), 328-336, 2014 | 68 | 2014 |
| Investigation of the effects of altered receptor binding activity on the clearance of erythropoiesis-stimulating proteins: nonerythropoietin receptor-mediated pathways may play … B Agoram, K Aoki, S Doshi, C Gegg, G Jang, G Molineux, L Narhi, S Elliott Journal of pharmaceutical sciences 98 (6), 2198-2211, 2009 | 48 | 2009 |
| Rilotumumab exposure–response relationship in patients with advanced or metastatic gastric cancer S Doshi, PO Gisleskog, Y Zhang, M Zhu, KS Oliner, E Loh, JJP Ruixo Clinical Cancer Research 21 (11), 2453-2461, 2015 | 45 | 2015 |
| Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expression M Zhu, R Tang, S Doshi, KS Oliner, S Dubey, Y Jiang, RC Donehower, ... British journal of cancer 112 (3), 429-437, 2015 | 45 | 2015 |
| Impact of target‐mediated elimination on the dose and regimen of evolocumab, a human monoclonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9) JP Gibbs, S Doshi, M Kuchimanchi, A Grover, MG Emery, MG Dodds, ... The Journal of Clinical Pharmacology 57 (5), 616-626, 2017 | 44 | 2017 |
| Pharmacodynamics of romiplostim alone and in combination with pegfilgrastim on acute radiation-induced thrombocytopenia and neutropenia in non-human primates K Wong, PY Chang, M Fielden, AM Downey, D Bunin, J Bakke, ... International journal of radiation biology 96 (1), 155-166, 2020 | 36 | 2020 |
| Tumor penetration and epidermal growth factor receptor saturation by panitumumab correlate with antitumor activity in a preclinical model of human cancer DJ Freeman, K McDorman, S Ogbagabriel, C Kozlosky, BB Yang, S Doshi, ... Molecular Cancer 11, 1-11, 2012 | 35 | 2012 |
| Denosumab dose selection for patients with bone metastases from solid tumors S Doshi, L Sutjandra, J Zheng, W Sohn, M Peterson, G Jang, AT Chow, ... Clinical Cancer Research 18 (9), 2648-2657, 2012 | 30 | 2012 |
| Blinatumomab pharmacodynamics and exposure–response relationships in relapsed/refractory acute lymphoblastic leukemia M Zhu, A Kratzer, J Johnson, C Holland, C Brandl, I Singh, A Wolf, ... The Journal of Clinical Pharmacology 58 (2), 168-179, 2018 | 29 | 2018 |
| Exposure‐response modeling of darbepoetin alfa in anemic patients with chronic kidney disease not receiving dialysis S Doshi, A Chow, JJP Ruixo The Journal of Clinical Pharmacology 50 (S9), 75S-90S, 2010 | 25 | 2010 |
| Clinical pharmacokinetics and pharmacodynamics of erythropoiesis-stimulating agents S Doshi, W Krzyzanski, S Yue, S Elliott, A Chow, JJ Pérez-Ruixo Clinical pharmacokinetics 52, 1063-1083, 2013 | 21 | 2013 |
| Comparison of LDL-C reduction using different evolocumab doses and intervals: biological insights and treatment implications SM Wasserman, MS Sabatine, MJ Koren, RP Giugliano, JC Legg, ... Journal of Cardiovascular Pharmacology and Therapeutics 23 (5), 423-432, 2018 | 16 | 2018 |
| Development of romiplostim for treatment of primary immune thrombocytopenia from a pharmacokinetic and pharmacodynamic perspective BB Yang, S Doshi, K Arkam, J Franklin, AT Chow Clinical Pharmacokinetics 55, 1045-1058, 2016 | 15 | 2016 |
| Population pharmacokinetics of blinatumomab in pediatric and adult patients with hematological malignancies JD Clements, M Zhu, M Kuchimanchi, B Terminello, S Doshi Clinical pharmacokinetics 59, 463-474, 2020 | 14 | 2020 |
| Romiplostim dose response in patients with immune thrombocytopenia JJ Perez‐Ruixo, B Green, S Doshi, YM Wang, DR Mould The Journal of Clinical Pharmacology 52 (10), 1540-1551, 2012 | 14 | 2012 |
| Pharmacokinetics and pharmacodynamics of rilotumumab: a decade of experience in preclinical and clinical cancer research Y Zhang, S Doshi, M Zhu British journal of clinical pharmacology 80 (5), 957-964, 2015 | 13 | 2015 |
